Grunenthal has been granted a patent for compounds that inhibit NaV1.8 and can be used for pain treatment. The invention is represented by a compound according to general formula (I). GlobalData’s report on Grunenthal gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Grunenthal, Human telomerase RT biomarker was a key innovation area identified from patents. Grunenthal's grant share as of May 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11999699B2) discloses a compound represented by a specific chemical formula (I) and various derivatives with different substituents. The compound can have substituents such as alkyl, cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, and others, as specified in the claims. Additionally, the patent covers compounds where certain substituents like R2, R4, and R5 have specific configurations, providing a detailed description of the permissible variations in the chemical structure.
Furthermore, the patent extends to pharmaceutical dosage forms containing the disclosed compounds and their use in treating pain. The method claims involve administering the compounds to individuals requiring pain treatment. The patent's scope includes compounds with specific substituents like S(O)2—CH3, C(O)NH2, OH, S(O)—CH3, or S(O)2—NH2, among others. Overall, the patent encompasses a range of chemical compounds, their pharmaceutical formulations, and therapeutic applications in pain management, highlighting the innovation and potential impact of the disclosed inventions in the field of pharmaceuticals and healthcare.
To know more about GlobalData’s detailed insights on Grunenthal, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
